Boostrix FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 12, 2022.
FDA Approved: Yes (First approved May 3, 2005)
Brand name: Boostrix
Generic name: tetanus, diphtheria, acellular pertussis vaccine (Tdap)
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis
Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) is a combination vaccine that provides immunization against pertussis (whooping cough) in combination with tetanus and diphtheria.
- Boostrix is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older; and immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.
- Boostrix is administered via intramuscular injection.
- Common solicited adverse reactions (≥15%) in adolescents (aged 10 to 18 years) were pain, redness, and swelling at the injection site; increase in arm circumference of the injected arm; headache; fatigue; and gastrointestinal symptoms.
Common solicited adverse reactions (≥15%) in adults (aged 19 to 64 years) were pain, redness, and swelling at the injection site; headache; fatigue; and gastrointestinal symptoms.
The most common solicited adverse reaction (≥15%) in the elderly (aged 65 years and older) was pain at the injection site.
Development timeline for Boostrix
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
